Baxter Healthcare Corporation

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Baxter Healthcare Corporation sits in the top decile of US sponsors by registered trial count (#393 of 15,742 sponsors by registered trial count).

46 total trials 1 currently recruiting 34 completed top decile by trial count

Baxter Healthcare Corporation: 46 sponsored US clinical trials, 1 recruiting.

Baxter Healthcare Corporation sponsors 46 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 34 completed. 12 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 2 trials.

Top-decile sponsor footprint

Baxter Healthcare Corporation ranks in the top decile of sponsors by registered trial count (#393 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 32/100

34 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

46 total, page 1 of 1

RECRUITING NA

Gen 2 Battrode Wear Study

NCT07256951

ACTIVE NOT RECRUITING

Tympanic Thermometer Study

NCT06556628

COMPLETED

Mobile Cardiac Telemetry (MCT) Study

NCT07158333

COMPLETED Phase 1

A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E

NCT06842134

COMPLETED Phase 1

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

NCT06842121

COMPLETED

PMCF Study for COSEAL® in Gynecologic Surgery

NCT05996809

COMPLETED NA

Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018

NCT06056011

COMPLETED

PMCF Study for ADEPT® in LaparoscopicGynecologic Surgery

NCT05811585

TERMINATED

DermaClose DUKE Fasciotomy and Wound Study

NCT05330767

COMPLETED Phase 1

Cefazolin PK Study 3g vs 2g

NCT05309304

TERMINATED NA

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

NCT05366010

COMPLETED Phase 4

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

NCT04555044

COMPLETED

Starling Registry Study

NCT04648293

TERMINATED NA

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by PIVA

NCT04324593

COMPLETED

Validation of a Sensor for Non-invasive Measurement of Stroke Volume and Cardiac Output

NCT04255108

COMPLETED Phase 1

Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects

NCT04155814

COMPLETED

Observational Study Using the CoVa Monitoring System 3

NCT03884582

COMPLETED

Validation of a Sensor for Non-Invasive Measurements

NCT03463148

COMPLETED

Remotely Monitoring Patients With Chronic Conditions in Their Home

NCT03207802

COMPLETED Phase 3

Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

NCT02891070

COMPLETED NA

Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding

NCT02640235

TERMINATED Phase 4

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994

COMPLETED

Necklace-Shaped Sensor for Non-Invasive Remote Monitoring of Vitals

NCT02337790

COMPLETED

Monitoring Subjects With Fluid-Management Issues In the Home Environment

NCT02190877

COMPLETED

Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis

NCT02140905

COMPLETED

Effects of IV Chloride Content on Outcomes

NCT02083198

TERMINATED Phase 4

Dosing Study of Amino Acids in Seriously Ill Patients

NCT01923480

COMPLETED Phase 4

Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

NCT01410240

TERMINATED

Veritas in Non-Bridging Ventral Hernia Repair

NCT01426477

TERMINATED Phase 4

Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis

NCT01234883

COMPLETED

Retrospective Analysis of Veritas in Breast Reconstruction

NCT01454713

COMPLETED Phase 2

Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty

NCT01112735

TERMINATED Phase 4

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

NCT01116102

COMPLETED Phase 3

Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

NCT00999141

TERMINATED

Bone Graft Materials Observational Registry

NCT00974623

COMPLETED Phase 3

FS VH S/D 500 S-apr in Vascular Surgery

NCT00892957

TERMINATED NA

The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer

NCT00958711

COMPLETED Phase 4

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

NCT00807885

COMPLETED Phase 2

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

NCT00708071

COMPLETED Phase 2

Fibrin Sealant for the Sealing of Dura Sutures

NCT00681824

COMPLETED Phase 2

Fibrin Sealant Vascular Surgery Study

NCT00576420

COMPLETED NA

Peri-Strips Dry (PSD) Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery

NCT00559013

COMPLETED NA

Reinforcement of Surgical Staple Lines Using Peri-Strips Dry (PSD) With Veritas Collagen Matrix

NCT00566943

COMPLETED Phase 3

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

NCT00157131

COMPLETED Phase 3

Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery

NCT00161733

COMPLETED Phase 1

Safety and Efficacy Study of Fibrin Sealant (FS 4IU) for Skin Graft Fixation and Wound Healing in Subjects With Burn Wounds

NCT00161759

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4
Phase 3 5
Phase 4 7

What is open in the Baxter Healthcare Corporation pipeline

1 recruiting of 46 indexed (2% open); 34 completed (74%).

Phase mix: 12 late (III/IV) vs 9 early (I/II) (balanced across stages).

Top condition: Hypertension (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Baxter Healthcare Corporation: open-pipeline peers nationwide

Peers matched on 46 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Baxter Healthcare Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150 0%10%20%30%40% Total trials Recruiting share Baxter Healthcare CorporationImmunityBioNational Institute of Nursing Research (NINR)University of Maryland, College ParkNew York Medical CollegeCenters for Disease Control and PreventionUSDA, Western Human Nutrition Research CenterSun Pharmaceutical IndustriesNSABP Foundation
Baxter Healthcare Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Baxter Healthcare Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 46 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

What to do with this Baxter Healthcare Corporation page

46 registered trials is a research-attention snapshot, not an endorsement of Baxter Healthcare Corporation or any single study.

  • 1 of Baxter Healthcare Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hypertension is the condition Baxter Healthcare Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Baxter Healthcare Corporation pipeline card: 46 registered trials from official public datasets.Report a data error.